Dihydroquinazolinones as 5HT modulators

Details Dihydroquinazolinones as 5HT modulators Dihydroquinazolinones as 5HT modulators

2007-07-03

2007-07-03

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S250000, C540S497000, C514S220000, C514S250000

Reexamination Certificate

active

11350997

ABSTRACT:
The present invention relates to modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating obesity using such compounds and compositions.

REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4379785 (1983-04-01), Weyer et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4572912 (1986-02-01), Yoshioka et al.
patent: 4639436 (1987-01-01), Junge et al.
patent: 4681893 (1987-07-01), Roth
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4904769 (1990-02-01), Rauenbusch
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5447954 (1995-09-01), Gribble et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5686104 (1997-11-01), Mills et al.
patent: 5698527 (1997-12-01), Kim
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5990109 (1999-11-01), Chen et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6358950 (2002-03-01), He et al.
patent: 6362180 (2002-03-01), Wilde et al.
patent: 6395767 (2002-05-01), Robl et al.
patent: 6399609 (2002-06-01), Wilde
patent: 6414002 (2002-07-01), Cheng et al.
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 6448261 (2002-09-01), Bakthavatchalam et al.
patent: 6515005 (2003-02-01), Dubowchik et al.
patent: 6515117 (2003-02-01), Ellsworth et al.
patent: 6518271 (2003-02-01), Gilligan et al.
patent: 6521636 (2003-02-01), Gilligan et al.
patent: 6525056 (2003-02-01), Arvanitis et al.
patent: 6573287 (2003-06-01), Sulsky et al.
patent: 6579876 (2003-06-01), Gilligan et al.
patent: 6589952 (2003-07-01), Bakthavatchalam et al.
patent: 6630476 (2003-10-01), Bakthavatchalam et al.
patent: 6635626 (2003-10-01), Barrish et al.
patent: 6642230 (2003-11-01), Wilde et al.
patent: 196 22 222 (1997-12-01), None
patent: 0 675 714 (1995-10-01), None
patent: 0 818 448 (1998-01-01), None
patent: 0 992 496 (2000-04-01), None
patent: 1 022 272 (2000-07-01), None
patent: 2 304 106 (1997-03-01), None
patent: WO 94/15592 (1994-07-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 97/35576 (1997-10-01), None
patent: WO 97/48701 (1997-12-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO99/42456 (1999-08-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/15201 (2000-03-01), None
patent: WO 00/30665 (2000-06-01), None
patent: WO 00/38722 (2000-07-01), None
patent: WO 00/50574 (2000-08-01), None
patent: WO 02/076973 (2002-10-01), None
patent: WO 02/083636 (2002-10-01), None
patent: WO 03/072197 (2003-09-01), None
patent: WO 2004/094425 (2004-11-01), None
Samoylenko, V.P., Synthesis of Novel Tricyclic Derivatives of 7-azabenorobornene System, Tetrahedron, 58, 6103-6110 (2002).
Berridge, M. et al., “Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands”, Biochem. J., vol. 206, pp. 587-595 (1982).
Biller, S. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, pp. 1-40 (1996).
Biller, S. et al., “Isoprenoid (Phosphinylmethyl) phosphonates as Inhibitors of Squalene Synthetase”, Journal of Medicinal Chemistry, vol. 31(10), pp. 1869-1871 (1988).
Chojnacka-Wojcik, E. et al., “Involvement of 5-HT2CReceptors in the m-CPP-Induced antinociception in Mice”, Pol. J. Pharmacol., vol. 46, pp. 423-428 (1994).
Corey, E. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration that “Presqualene Pyrophosphate” is an essential Intermediate on the Path to Squalene”, J. of the American Chemical Soc., vol. 98(5), pp. 1292-1293 (1976).
Cryan, J. et al., “Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine2cReceptors1”, The J. of Pharmacology & Experimental Therapeutics, vol. 295(3), pp. 1120-1126 (2000).
DiMatteo, V. et al., “Role of 5-HT2creceptors in the control of central dopamine function”, TRENDS in Pharmacological Sciences, vol. 22(5), pp. 229-232 (2001).
Egan, C. et al., “Agonist activity of LSD and lisuride at cloned 5HT2Aand 5HT2Creceptors”, Psychopharmacology, vol. 136, pp. 409-414 (1998).
Fitzgerald, L. et al., “High-Affinity Agonist binding Correlates with Efficacy (Intrinsic Activity) at the Human Serotonin 5-HT2Aand 5-HT2cReceptors: Evidence Favoring the Ternary Complex and Two-State Models of Agonist Action”, J. of Neurochemistry, vol. 72(5), pp. 2127-2134 (1999).
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”, Cardiovascular Drug Reviews, vol. 16(1), pp. 16-30, (1998).
Glennon, R. et al., “[125|]-1-(2,5-Dimethoxy-4-iodophenyl)-2-amino-propane: An Iodinated Radioligand that specifically Labels the Agonist High-Affinity State of 5-HT2Serotonin Receptors”, J. Med. Chem., vol. 31, pp. 5-7 (1988).
Grottick, A. et al., “Studies to Investigate the Role of 5-HT2CReceptors on Cocaine- and Food-Maintained Behavior1”, The J. of Pharmacology and Experimental Therapeutics, vol. 295(3), pp. 1183-1191 (2000).
Grottick, A. et al., “Activation of 5-HT2Creceptors reduces the locomotor and rewarding effects of nicotine”, Psychopharmacology, vol. 157, pp. 292-298 (2001).
Hara, S., “Ileal Na+/bile acid cotransporter inhibitors”, Drugs of the Future, vol. 24(4), pp. 425-430 (1999).
Hoffman, B. et al., “Distribution of serotonin 5-HT1Creceptor mRNA in adult rat brain”, FEBS Letters, vol. 247(2), pp. 453-462 (1989).
Hollenbaugh, D. et al., “Cleavable CD40Ig fusion proteins and the binding to sgp39”, J. of Immunological Methods, vol. 188, pp. 1-7 (1995).
Hollenbaugh, D. et al., “The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity”, The EMBO Journal, vol. 11(12), pp. 4313-4321 (1992).
Horlick, R. et al., “Rapid generation of Stable Cell Lines Expressing Corticotropin-Releasing Hormone Receptor for Drug Discovery”, Protein Expression and Purification, vol. 9, pp. 301-308, (1997).
Hoyer, D. et al., “VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin)”, Pharmacological Reviews, vol. 46(2), pp. 157-203 (1994).
Krause, B. et al., “ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals”, Inflammation: Mediators and Pathways, pp. 173-198 (1995).
Leonhardt, S. et al., “Molecular Pharmacological Differences in the Interaction of Serotonin with 5-Hydroxytryptamine1cand 5-Hydroxytryptamine2Receptors”, Molecular Pharmacology, vol. 42, pp. 328-335 (1992).
Lucaites, V. et al., “Receptor Subtype and Density Determine the Coupling Repertoire of the 5-HT2Receptor Subfamily”, Life Sciences, vol. 59(13), pp. 1081-1095 (1996).
Mazzola-Pomietto, P. et al., “Evidence thatm-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2creceptor

Affiliated with

Also associated with

Rating

Dihydroquinazolinones as 5HT modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dihydroquinazolinones as 5HT modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydroquinazolinones as 5HT modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3818076